<DOC>
	<DOCNO>NCT01131351</DOCNO>
	<brief_summary>The purpose study : - To evaluate safety tolerability orally administer OPC-67683 administer two time daily ( BID ) MDR TB patient refractory treatment optimize background regimen anti-TB medication ( OBR ) . - To evaluate pharmacokinetics ( PK ) OPC-67683 metabolite .</brief_summary>
	<brief_title>Safety Pharmacokinetics ( PK ) Multidrug-Resistant ( MDR ) Refractive Tuberculosis</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<criteria>1 . Provide write , informed consent prior trialrelated procedure 2 . Male female patient age 18 64 year , inclusive . 3 . Able produce sputum mycobacterium culture able obtain sputum produce Induction . 4 . At least three sputum mycobacterium culture positive MTB invitro resistance isoniazid rifampicin previous 270 day ( 9 month ) despite treatment first second line antiTB drug , include one positive culture within previous 60 day time sputum collection , prior date screen initiation ( defined date ICF sign screen begin ) . 5 . Sputum mycobacterial culture positive MTB invitro susceptibility least one antiTB Medication within previous 60 day prior date screen initiation . 6 . Patient judge investigator potential clinical benefit OPC67683 exposure . 7 . Female patient childbearing potential must negative urine pregnancy test agree use highly effective method birth control ( example , two follow precaution : tubal ligation , vaginal diaphragm , intrauterine device , oral contraceptive , contraceptive implant , combine hormonal patch , combine injectable contraceptive depotmedroxyprogesterone acetate ) throughout participation trial 22 week last dose ( cover duration ovulation ) . 8 . Male patient must agree use adequate method contraception ( double barrier ) throughout participation trial 30 week last dose ( cover duration spermatogenesis . 1 . A history allergy nitroimidazoles nitroimidazole derivative time . 2 . Use medication Section 4.1 include : use amiodarone time previous 12 month , use antiarrhythmic previous 30 day , well use certain antidepressant , Antihistamines , macrolides , previous 14 day . 3 . Any current serious concomitant condition renal impairment characterize serum creatinine level ≥265 μmol/L hepatic impairment characterize ALT and/or aspartate transferase ( AST ) level 3 time upper limit laboratory reference range . 4 . Current clinically relevant change Screening ECG atrioventricular ( AV ) block , prolongation QRS complex 120 msec ( male female patient ) , QTcF interval 450 msec male patient 470 msec female patient . 5 . Current clinically relevant cardiovascular disorder heart failure , coronary heart disease , uncontrolled poorly control hypertension , arrhythmia , tachyarrhythmia status myocardial infarction . 6 . For patient HIV infection , CD4 cell count &lt; 350/mm3 treatment antiretroviral medication HIV infection . 7 . Karnofsky score &lt; 50 % . 8 . Any current disease condition use nitroimidazoles nitroimidazole derivates contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>MDR-TB</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Phase II</keyword>
	<keyword>Open Label</keyword>
	<keyword>Non Controlled</keyword>
	<keyword>Pulmonary Multidrug-Resistant Tuberculosis ( MDR TB )</keyword>
</DOC>